Latanoprostene
Latanoprostene bunod is a prostaglandin analogue and nitric oxide-donating medicine used to reduce elevated intraocular pressure in adults with open-angle glaucoma or ocular hypertension. It works through two complementary mechanisms: its active metabolite increases aqueous humour outflow through the uveoscleral pathway, while nitric oxide relaxes the trabecular meshwork and improves drainage through the conventional outflow pathway. It is commonly available as a sterile ophthalmic solution administered as eye drops once daily in the affected eye or eyes. Common side effects include eye redness, irritation, eye pain, blurred vision, and eyelash changes. Important precautions include monitoring intraocular pressure and watching for changes in iris pigmentation, inflammation, or macular oedema in susceptible patients. Latanoprostene bunod should be used under ophthalmological supervision, and contact lenses should be removed before application and reinserted after the recommended interval.
Latanoprostene was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Latanoprostene, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Latanoprostene from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Latanoprostene, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
